WHO says Ebola outbreak in DRC remains high as violence hampers response
The World Health Organization warns that Ebola transmission in the Democratic Republic of the Congo stays at a high level, with weekly case numbers unchanged and attacks on health facilities worsening containment efforts.
The World Health Organization (WHO) said the Ebola outbreak in the Democratic Republic of the Congo (DRC) remains at a "high" and "sustained" level nearly six months after it was declared on May 15. About 400 to 500 new cases are still being reported each week, according to WHO regional emergency director for Africa Marie Roseline Belizaire, who described the overall situation as "concerning" during an online press briefing.
DRC health authorities have recorded 11,114 confirmed cases and 5,433 deaths as of Nov 10, a case-fatality rate of 48.9 percent, affecting 67 health zones across eight provinces. While infections fell in Ituri Province, the initial epicenter, cases in neighboring North Kivu rose by 31 percent in the 21 days ending Nov 7.
WHO incident manager for the Ebola response Catherine Smallwood said most new infections are now concentrated in a few areas where armed conflict, displacement and mistrust impede response work. She noted that Mahagi in Ituri reported new cases after a 90-day lull, underscoring the risk of resurgence.
Insecurity has become a major obstacle. WHO verified 81 attacks on health facilities since the outbreak began. An armed assault on Nov 5 in Cantine-Aloya, North Kivu, killed 66 civilians, including three health workers, and resulted in looting and burning of three health sites. Subsequent attacks in the Mabalako health zone forced further displacement and halted response activities. Belizaire called for an "urgent halt in hostilities and violence" so that health workers can reach affected communities safely.
Recent imported cases in Kenya and Nigeria have raised concerns about cross-border spread, but both countries have so far contained the virus, with no new confirmed cases reported in the latest reporting period. Kenya recorded nine cases, all linked to a single imported infection, and Nigeria reported one imported case that was evacuated for treatment.
The WHO said it is strengthening surveillance and preparedness in neighboring states, including the Central African Republic and South Sudan. On Nov 4, the agency announced that two experimental vaccines targeting the Bundibugyo Ebola virus—ChAdOx1 and Moderna’s mRNA-1469—have been recommended for inclusion in the ongoing Tumaini Phase 2/3 trial in Bunia, Ituri Province. Initial trial results are expected in early 2027, while clinical studies of experimental treatments continue. No vaccine or specific therapy has yet been approved for the Bundibugyo strain.